Evidence map›Paper›PMID 28817744›Full record

Trial reportJAMA ophthalmology2017

Predictors of Corneal Perforation or Need for Therapeutic Keratoplasty in Severe Fungal Keratitis: A Secondary Analysis of the Mycotic Ulcer Treatment Trial II.

N Venkatesh Prajna, Tiruvengada Krishnan, Revathi Rajaraman, Sushila Patel, Ranjeet Shah, Muthiah Srinivasan, Manoranjan Das, Kathryn J Ray, Catherine E Oldenburg, Stephen D McLeod and 5 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA ophthalmology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00996736 (Mycotic Ulcer Treatment Trial), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00996736 phase3completednot on this map

Mycotic Ulcer Treatment Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2012Enrolled323ConditionsCorneal Ulcer, Eye Infections, FungalArmsNatamycin, Voriconazole
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 3 countries.

N Venkatesh PrajnaAravind Eye Care System, Madurai, Pondicherry, Tirunelveli and Coimbatore, India.
Tiruvengada KrishnanAravind Eye Care System, Madurai, Pondicherry, Tirunelveli and Coimbatore, India.
Revathi RajaramanAravind Eye Care System, Madurai, Pondicherry, Tirunelveli and Coimbatore, India.
Sushila PatelLumbini Eye Hospital, Bhairahawa, Nepal.
Ranjeet ShahBharatpur Eye Hospital, Bharatpur, Nepal.
Muthiah SrinivasanAravind Eye Care System, Madurai, Pondicherry, Tirunelveli and Coimbatore, India.
Manoranjan DasAravind Eye Care System, Madurai, Pondicherry, Tirunelveli and Coimbatore, India.
Kathryn J RayFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Catherine E OldenburgFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Stephen D McLeodFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Michael E ZegansDartmouth Medical School, Lebanon, New Hampshire.
Nisha R AcharyaFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Thomas M LietmanFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Jennifer Rose-NussbaumerFrancis I. Proctor Foundation, University of California-San Francisco, San Francisco.
Mycotic Ulcer Treatment Trial Group
Aravind Eye Hospital · INUniversity of California, San Francisco · USBiratnagar Eye Hospital · NPLumbini Eye Institute · NPSan Francisco Foundation · US

Funding

Myocotic Ulcer Treatment TrialU10EY018573 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIETMAN, THOMAS M · 2009 to 2014
$3.7M
Predictions of Response to Treatment in Fungal KeratitisK23EY025025 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSE-NUSSBAUMER, JENNIFER · 2015 to 2019
$1.2M
NEI NIH HHS K23 EY025025NEI NIH HHS U10 EY018573
6 · The paper itself

Abstract

Importance: Identifying patients with infectious keratitis who are at risk of experiencing a poor outcome may be useful to allocate resources toward high-risk patients, particularly in resource-poor settings. Objective: To determine baseline patient and ulcer characteristics that predict a high risk of developing corneal perforation and/or the need to undergo therapeutic penetrating keratoplasty (TPK). Design, Setting, and Participants: This is a secondary analysis of Mycotic Ulcer Treatment Trial II, a multicenter, double-masked, placebo-controlled randomized clinical trial that enrolled 240 patients with smear-positive filamentous fungal corneal ulcers who enrolled between May 2010 and August 2015. Participants had a baseline visual acuity of 20/400 or worse and were randomized to receive oral voriconazole or a placebo (all participants received topical voriconazole, 1%). After 39 participants (16.3%) were enrolled, topical natamycin, 5%, was also added. Main Outcomes and Measures: The primary outcome of this secondary analysis was the rate of corneal perforation or the need to undergo TPK. Results: The mean (SD) age at enrollment was 49 (13) years, 104 participants (43.3%) were women, and all were of Southeast Asian descent. The presence of hypopyon at baseline indicated 2.28 times the odds of the patient developing corneal perforation and/or needing TPK (95% CI, 1.18-4.40; P = .01). Study participants whose infiltrate involved the posterior one-third had a 71.4% risk of developing corneal perforation and/or needing TPK. For each 1-mm increase in the geometric mean of the infiltrate, there was 1.37 (95% CI, 1.12-1.67; P = .002) increased odds of developing perforation and/or needing TPK. Other clinical features such as visual acuity, baseline culture positivity, type of filamentous fungal organism and duration of symptoms, and demographic characteristics, such as sex and occupation, were not significant predictors in the multivariable regression analysis. Conclusions and Relevance: These results suggest that risk stratification from baseline ulcer characteristics can identify those at highest risk for developing corneal perforation and/or needing TPK. Trial Registration: clinicaltrials.gov Identifier: NCT00996736.

Indexed as

Keratoplasty, PenetratingAdministration, OralAdultAntifungal AgentsCorneal PerforationCorneal UlcerDouble-Blind MethodDrug Therapy, CombinationEye Infections, FungalFemaleHumansMaleMiddle AgedMycosesNatamycinSuppurationAntifungal AgentsNatamycinVoriconazole

Identifiers

PMID28817744
PMCPMC6038821
OpenAlexW2747374014

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.